期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白血病免疫治疗的研究进展 被引量：1

The Research Progress of Leukemia Immunotherapy
下载PDF
导出
摘要 20世纪90年代以来,白血病的治疗已经取得了令人瞩目的成果,免疫治疗最初的目的是激发和增强机体免疫功能,从而控制和杀灭白血病细胞。随着分子生物学、细胞生物学、遗传学及基因重组技术的快速发展,免疫治疗作为肿瘤治疗的一种手段,表现出多样性,不同的免疫治疗其抗肿瘤作用机制也不尽相同,靶细胞也各异,针对不同类型的白血病产生不同的治疗效果。随着对抗肿瘤作用机制的深入研究,单独针对白血病细胞的免疫治疗也获得成功,并逐渐总结出白血病免疫治疗的一般原则,改善了白血病的预后,为白血病的治疗开辟了广阔的发展前景。 Since 1990s, leukemia treatment has made remarkable achievements. The initial purpose of immunotherapy is to stimulate and strengthen cells. As the rapid development of moleeular biology, cell hiology,genetics and genetie recombination teehnology,immunotherapy shows diversity as a means of cancer treatment. Anti-tumor mechanisms are different for different immunotherapies and the target cells are varied, and different treatment effects are produced for different types of leukemia. With the deepening of research of the antitumor mechanism,immunolherapy against leukemia cells alone also succeeds,and the general prineiple of eukem a mmunotherapy has been summarized gradually ,which opens up a broad prospect for the treatment of leukemia.
作者 王转平 张连生
机构地区 兰州大学第二医院血液科
出处 《医学综述》 2013年第21期3928-3931,共4页 Medical Recapitulate
关键词 白血病 免疫治疗 单克隆抗体 肿瘤疫苗 Leukemia Immunothcrapy Monoclonal antibody Tumor vaccine
分类号 R733.7 [医药卫生—肿瘤] R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Nageswara Rao AA, Kumar R, Ahaf S, et al. Pretransplant condi- tioning with Campath-lH i alemtuzumab )in pediatric matched unrelated hemato-poietic stem cell transplants: an institutional experience[ J]. J Pediatr Hemat] Oneo1,2012,34(2) :96-100.
  • 2Austin FC, Boone CW. Virus augmentation of the antigenicity of tumor cell extraeta [J]. Adv Cancer Res, 1979,30 : 301-345.
  • 3Dunussi-Joannopoulos K, Weinstein H J, Niekerson PW, et al. Irra- diated B7-1 transduced primmy acute myelogemms leukemia (AML)eelIs can be used as therapeutic vaccines in murine AMI, [ J ]. Blood, 1996,87 ( 7 ) : 2938-2946.
  • 4Stripeeke R, Caxloso AA, Pepper KA, et hi. lntiviral veetors for efficient delivery of CDs0 and granuloeyte-maerophage-eohmy-stim- ulating factor in human acute tymphoblastie leukemia and aeute myeloid leukemia cells to imluee antileukemic, immune sponses [ J ]. Blood,2000,96 (4) : 1317-1326.
  • 5Enright H, McGlave PB. Chrnnic myelogenous leukemia [ J ]. Curr Opin Hematol, 1996,3(4) :303-309.
  • 6Yano K,Lijima K, Sao H,et al. Molecular remission achieved by interferon therapy in a patient with cytogenetically relapsed chronic myelogenous leukemia after syngeneic bone marrow transplantation [ J ]. Int J Hematol, 1996,64 ( 3/4 ) : 267-270.
  • 7Blankenstein T, Qin Z. The role of IFN-/ in tumor transplantation immunity and inhibition of chemical carcino-genesis [J]. Curr Opin immunol, 2003,15 ( 2 ) : 148-154.
  • 8Moreton P, Kennddy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after ale- mtuzumab therapy is associated with prolonged survival [ J ]. J Chinical Ooco1,2005,23 ( 13 ) :2971-29"/9.
  • 9Tsimberidou AM, Giles EJ,Estey E,et al. The role of gemtuzumab ozogamicin in acute leukemia therapy [ J ]. Br J Haemat01,2006, 132(4) :398409.
  • 10Boland A, Bagus A, Hockenhull J, et al. Rituximab for the treat- ment of relapsed or refractory Hodgkin, slymphoma [J ]. Health 2) :41-48.

二级参考文献16

  • 1Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood, 2003, 101:1698-1704.
  • 2Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessement of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia, 2002, 16:2115-2121.
  • 3Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia, 2002,16:1381-1389.
  • 4Cazzaniga G, Rossi V, Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood acute lymphoblastic leukemia. Best Pract Res Clin Haematol, 2002,15: 21-35.
  • 5Szczepanski T, Flohr T, Van der Velden VH, et al. Molecular monitoring of residual disease using antigen receptor genes in childhhood acute lymphoblastic leukemia. Best Pract Res Clin Haematol, 2002,15: 37-57.
  • 6Crimwade D. The significance of minimal residual disease in pationts with t(15;17). Best Pract Res Clin Haematol, 2002,15: 137-158.?A
  • 7Liu Yin JA . Minimal residual disease in acute myeloid leukemia. Best Pract Res Clin Haematol, 2002,15: 119-135.
  • 8Menssen HD, Siehl JM, Thiel E. Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol, 2002,76:103-109.
  • 9Hosen N, Sonoda Y, Oji Y,et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms′ tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol, 2002, 116:409-420.
  • 10Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia, 2003, 17: 1301-1312.

共引文献45

同被引文献29

  • 1Bernstein I D,Tam M R,Nowinski R C.Mouse leukemia:therapy with monoclonal antibodies against a thymus differentiation antigen.Science,1980;207(4426)∶68~71.
  • 2Best M,Streisand R,Catania L,et al.Parental distress during pediatric leukemia and posttraumatic stress symptoms(PTSS)after treatment ends.Journal of pediatric psychology,2001;26(5)∶299~307.
  • 3Carter B Z,Mak D H,Schober W D,et al.Triptolide induces caspasedependent cell death mediated via the mitochondrial pathway in leukemic cells.Blood,2006;108(2)∶630~637.
  • 4Yoshida M,Yamamoto M,Nikaido T.Quercetin arrests human leukemic T-cells in late G1phase of the cell cycle.Cancer Research,1992;52(23)∶6676~6681.
  • 5Pace-Asciak C R,Hahn S,Diamandis E P,et al.The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis:implications for protection against coronary heart disease.Clinica Chimica Acta,1995;235(2)∶207~219.
  • 6Formica J V,Regelson W.Review of the biology of quercetin and related bioflavonoids.Food and chemical toxicology,1995;33(12)∶1061~1080.
  • 7Kim J H,Kim S H,Alfieri A A,et al.Quercetin,an inhibitor of lactate transport and a hyperthermic sensitizer of He La cells.Cancer research,1984;44(1)∶102~106.
  • 8Jung Y H,Heo J,Lee Y J,et al.Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5.Life sciences,2010;86(9)∶351~357.
  • 9Horvathova K,Novotn?L,Tothova D,et al.Determination of free radical scavenging activity of quercetin,rutin,luteolin and apigenin in H2O2-treated human ML cells K562.Neoplasma,2003;51(5)∶395~399.
  • 10Enari M,Sakahira H,Yokoyama H,et al.A caspase-activated DNase that degrades DNA during apoptosis,and its inhibitor ICAD.Nature,1998;391(6662)∶43~50.

引证文献1

二级引证文献4

医学综述
2013年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部